STUDY OF D-DIMER AND SERUM FERRITIN LEVELS AS PROGNOSTIC BIOMARKERS IN COVID-19 PATIENTS
DOI:
https://doi.org/10.22159/ajpcr.2022.v15i12.46338Keywords:
COVID-19 patients, Cytokine storm, D-dimer, Ferritin, Hyperinflammation, Hyperferritinemia, Pro-inflammatory cytokinesAbstract
Objective: Coronavirus disease 2019 (COVID-19) is primarily a respiratory illness causing thrombotic disorders. Pro-inflammatory cytokines are one of the responsible causes of cytokine storm syndrome in patients with COVID-19. Coagulopathy and inflammation are associated with COVID-19 severity. The coronavirus spike protein facilitates the entry of the virus into the target cells causing coagulopathy and inflammation.Other infections include direct viral toxicity, endothelial cell damage, inflammation, and deregulation of the immune response and renin-angiotensin-aldosterone system. The study aims to estimate levels of D-Dimer and Serum Ferritin in symptomatic and asymptomatic COVID-19 patients and its comparison with healthy controls.
Methods: The study includes 30 healthy control and 30 symptomatic and 30 asymptomatic COVID-19 patients of both sexes. Analysis of serum ferritin was done on a fully automated immunology analyzer-SIEMENS based on the principle of chemiluminescence. D-dimer was estimated on mLab which is cartridge-based.
Results: We observed that the levels of D-Dimer and Serum Ferritin significantly increased in symptomatic COVID-19 patients as compared to asymptomatic COVID-19 positive patients and healthy non-COVID-19 controls.
Conclusion: The elevated serum ferritin and D-dimer were associated with a poor outcome and poor prognosis and could predict the worsening of COVID-19 patients. The significant increase showed that D-Dimer and serum ferritin accurately predicts patients developing severe COVID- infection.
Downloads
References
Farasani A. Biochemical role of serum ferritin and d-dimer parameters in COVID-19 diagnosis. Saudi J Biol Sci 2021;28:7486-90. doi: 10.1016/j.sjbs.2021.08.040, PMID 34429685
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3. doi: 10.1038/s41586-020-2012-7, PMID 32015507
World Health Organization. Coronavirus Disease 2019 (COVID-19) Situation Report. Geneva: World Health Organization; 2020.
Krajewska J, Krajewski W, Zub K, Zatoński T. COVID-19 in otolaryngologist practice: A review of current knowledge. Eur Arch Otorhinolaryngol 2020;277:1885-97. doi: 10.1007/s00405-020- 05968-y, PMID 32306118
Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol 2020;92:797-806. doi: 10.1002/jmv.25783, PMID 32198776
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13. doi: 10.1016/S0140-6736(20)30211-7, PMID 32007143
Li Y, Shi J, Xia J, Duan J, Chen L, Yu X, et al. Asymptomatic and symptomatic patients with non-severe coronavirus disease (COVID-19) have similar clinical features and virological courses: A retrospective single-center study. Front Microbiol 2020;11:1570. doi: 10.3389/ fmicb.2020.01570, PMID 32754137
Li X, Wang W, Zhao X, Zai J, Zhao Q, Li Y, et al. Transmission dynamics and evolutionary history of 2019-nCov. J Med Virol 2020;92:501-11. doi: 10.1002/jmv.25701, PMID 32027035
Patel A, Jernigan DB. N-CoV CDC Response Team. Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak-United state, December 31, 2019-February 2, 2020. MMWR Morb Mortal Wkly Rep 2019;69:140-6.
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020;26:1017-32. doi: 10.1038/s41591-020-0968-3, PMID 32651579
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020;383:120-8. doi: 10.1056/ NEJMoa2015432, PMID 32437596
Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology 2021;88:15-27. doi: 10.1159/000512007, PMID 33049751
Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19 related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost 2020;120:998-1000. doi: 10.1055/s-0040-1710018, PMID 32316063
Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020;58:1116-20. doi: 10.1515/cclm-2020-0188, PMID 32172226
Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients with SARS-CoV-2 in Wuhan. China. Allergy 2020;75:1730-41.
Griffin DO, Jensen A, Khan M, Chin J, Chin K, Saad J, et al. Pulmonary embolism and increased levels of D-dimer in patients with coronavirus disease. Emerg Infect Dis 2020;26:1941-3. doi: 10.3201/ eid2608.201477, PMID 32348233
Yameny AA. Ferritin as a biomarker of infection in Covid-19 non-hospitalized patients. J Biosci App Res 2021;7:23-8.
Perricone C, Bartoloni E, Bursi R, Cafaro G, Guidelli GM, Shoenfeld Y, et al. COVID-19 as part of the hyperferritinemia syndromes: The role of iron depletion therapy. Immunol Res 2020;68:213-24.
Kappert K, Jahić A, Tauber R. Assessment of serum ferritin as a biomarker in COVID-19: Bystander or participant? Insights by comparison with other infectious and non-infectious diseases. Biomarkers 2020;25:616-25. doi: 10.1080/1354750X.2020.1797880, PMID 32700561
Cheng L, Li H, Li L, Liu C, Yan S, Chen H, et al. Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Lab Anal 2020;34:e23618. doi: 10.1002/jcla.23618, PMID 33078400
Zhou B, She J, Wang Y, Ma X. Utility of ferritin, procalcitonin and C-reactive protein in severe patients with 2019 novel coronavirus disease. 2020; 395: 1054-1062.
Qin Z, Zhang X, Chen Z, Liu N. Establishment and validation of an immune-based prognostic score model in glioblastoma. Int Immunopharmacol 2020;85:106636. doi: 10.1016/j.intimp.2020.106636, PMID 32534425
Published
How to Cite
Issue
Section
Copyright (c) 2022 Suman Jain, Dr Suman Jain, Dr Anju Bapna, Dr Sonal Sogani
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
